Effect of Curcumin-Piperine in moderate-to-high hepatic steatosis

The effects of curcumin plus piperine supplementation on cardiometabolic risk factors and fibroscan findings in patients with moderate-to-high hepatic steatosis : a randomized double blind placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121216011763N47

Enrollment

Registered

2020-05-14

Start date

2020-09-22

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease (NAFLD). Abnormal results of liver function studies

Interventions

Intervention 1: Intervention group: A daily curcumin-piperine capsule(500 mg curcumin+ 5 mg piperine) will receive after meal for 12 weeks. Intervention 2: Control group: A daily placebo capsule(500 m

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Willingness to participation in the study Age 18-65 years Evidence indicating non alcoholic fatty liver disease (NAFLD) white grade 2 and 3 diagnosed with sonography.

Exclusion criteria

Exclusion criteria: Alcohol use People with heart , pulmonary and kidney diseases, hepatitis, cirrhosis, biliary and immune disorders, hypertension, diabetes, hypothyroidism and Cushing's syndrome Consumption of Metformin, Vitamin E, Orsodeoxycholic acid, Phenytoin, tamoxifen, Lithium, Corticosteroids and Methotrexate within three months of the study. Weight loss or bariatric surgery in recent years Pregnancy Supplement intolerance and unexpected adverse effects

Design outcomes

Primary

Measure	Time frame
Triglyceride (TG). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Total Cholesterol (TC). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Low density lipoprotein (LDL). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;High density lipoprotein (HDL). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Digital scale.;Waist Circumference (WC). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Non-stretching tape measure.;Body mass index (BMI). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Dividing the weight into kilograms by squared height by meter.;Aspartate aminotransferase (AST). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Alanine aminotransferase (ALT). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Hepatic steatosis and fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;Fasting blood sugar (FBS). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic.;Blood pressure. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Sphygmomonometer.;Serum levels of High sensitive C-reactive protein (Hs-CRP). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.	—

Measure

Time frame

Triglyceride (TG). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Total Cholesterol (TC). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Low density lipoprotein (LDL). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;High density lipoprotein (HDL). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Digital scale.;Waist Circumference (WC). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Non-stretching tape measure.;Body mass index (BMI). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Dividing the weight into kilograms by squared height by meter.;Aspartate aminotransferase (AST). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Alanine aminotransferase (ALT). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic photometric method.;Hepatic steatosis and fibrosis. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Fibroscan.;Fasting blood sugar (FBS). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzymatic.;Blood pressure. Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Sphygmomonometer.;Serum levels of High sensitive C-reactive protein (Hs-CRP). Timepoint: Before intervention and 12 weeks after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA) kits.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza askari

Esfahan University of Medical Sciences

askari@mui.ac.ir+98 31 3668 1378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026